Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral Janus kinase inhibitors for atopic dermatitis. Annals Allergy Asthma Immunology. 2023;130(5):577–92. https://doi.org/10.1016/j.anai.2023.01.020.

Article  CAS  Google Scholar 

Zhao A, Pan C, Li M. Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: opportunities and challenges. Pediatr Invest. 2023;7(3):177–90. https://doi.org/10.1002/ped4.12400.

Article  CAS  Google Scholar 

Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681–5. https://doi.org/10.1016/j.jaci.2023.01.010.

Article  PubMed  Google Scholar 

Amy S, Paller S, Butala. William Howe. Treatment of atopic dermatitis (Eczema). Uptodate; 2024.

Keam SJ. Lebrikizumab: first approval. Drugs. 2024;84(3):347–53. https://doi.org/10.1007/s40265-024-02000-z.

Article  PubMed  CAS  Google Scholar 

Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 2024;25(4):655–68. https://doi.org/10.1007/s40257-024-00859-y.

Article  PubMed  PubMed Central  Google Scholar 

Geba GP, Li D, Xu M, et al. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–66. https://doi.org/10.1016/j.jaci.2022.08.026.

Article  PubMed  CAS  Google Scholar 

Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1):158–e1671. https://doi.org/10.1016/j.jaad.2018.07.048.

Article  PubMed  CAS  Google Scholar 

Siegfried EC, Wine Lee L, Spergel JM, et al. A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Pediatr Dermatol. 2024;41(2):204–9. https://doi.org/10.1111/pde.15518.

Article  PubMed  Google Scholar 

Lieberman JA, Chu DK, Ahmed T et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology. Published online June 5, 2024. https://doi.org/10.1016/j.anai.2024.05.014

Marshall GD, Tracy JM. Is it safe and effective to give live viral vaccines to patients on biologics? Annals of allergy, asthma, & immunology. Published online 2024. https://doi.org/10.1016/j.anai.2024.06.031

Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628–36. https://doi.org/10.1016/j.jaad.2021.06.017.

Article  PubMed  CAS  Google Scholar 

Mickevicius T, Pink AE, Bhogal M, O’Brart D, Robbie SJ, Dupilumab-Induced. Tralokinumab-Induced, and Belantamab Mafodotin–Induced adverse ocular Events—Incidence, etiology, and management. Cornea. 2023;42(4):507. https://doi.org/10.1097/ICO.0000000000003162.

Article  PubMed  Google Scholar 

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47. https://doi.org/10.1016/j.jaad.2020.08.051.

Article  PubMed  CAS  Google Scholar 

Achten R, Dekkers C, Bakker D, et al. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clinical Experimental Allergy. 2023;53(5):586–9. https://doi.org/10.1111/cea.14305.

Article  PubMed  Google Scholar 

Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248–9. https://doi.org/10.1111/bjd.17538.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021;38(2):390–4. https://doi.org/10.1111/pde.14499.

Article  PubMed  Google Scholar 

Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60(1):125–36. https://doi.org/10.1016/j.jaad.2008.07.058.

Article  PubMed  Google Scholar 

Leonard A, Guttman-Yassky E. The Unique Molecular Signatures of Contact Dermatitis and implications for treatment. Clin Rev Allerg Immunol. 2019;56(1):1–8. https://doi.org/10.1007/s12016-018-8685-0.

Article  CAS  Google Scholar 

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. https://doi.org/10.1111/bjd.19574.

Article  PubMed  CAS  Google Scholar 

Study Details | Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 | ClinicalTrials.gov. Accessed July 21. 2024. https://clinicaltrials.gov/study/NCT03556592?intr=tralokinumab&cond=Atopic%20Dermatitis&rank=19

Study Details | Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 | ClinicalTrials.gov. Accessed July 21. 2024. https://clinicaltrials.gov/study/NCT03761537?intr=tralokinumab&cond=Atopic%20Dermatitis&rank=10#study-overview

Paller AS, Flohr C, Cork M, et al. Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatology. 2023;159(6):596–605. https://doi.org/10.1001/jamadermatol.2023.0627.

Article  PubMed  PubMed Central  Google Scholar 

Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–24. https://doi.org/10.1016/j.jaad.2022.07.019.

Article  PubMed  CAS  Google Scholar 

Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71–8. https://doi.org/10.1016/j.jaad.2021.03.032.

Article  PubMed  CAS  Google Scholar 

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of Lebrikizumab for Moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91. https://doi.org/10.1056/NEJMoa2206714.

Article  PubMed  CAS  Google Scholar 

Study Details | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to < 18 Years of Age With Moderate-to-Severe Atopic Dermatitis | ClinicalTrials.gov. Accessed July 20. 2024. https://clinicaltrials.gov/study/NCT05559359?intr=Lebrikizumab&cond=Atopic%20Dermatitis&rank=17

Paller AS, Flohr C, Eichenfield LF, et al. Safety and Efficacy of Lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, Open-Label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517–34. https://doi.org/10.1007/s13555-023-00942-y.

Article  PubMed  Google Scholar 

Igarashi A, Katsunuma T, Matsumura T, Komazaki H, for the Nemolizumab-JP04 Study Group. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol. 2024;190(1):20–8. https://doi.org/10.1093/bjd/ljad268.

Article  Google Scholar 

Sidbury R, Alpizar S, Laquer V, et al. Pharmacokinetics, Safety, Efficacy, and Biomarker profiles during Nemolizumab Treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb). 2022;12(3):631–42. https://doi.org/10.1007/s13555-021-00678-7.

Article  PubMed  Google Scholar 

Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482–e4937. https://doi.org/10.1016/j.jaci.2018.11.053.

Article  PubMed  CAS  Google Scholar 

Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunology: Global. 2024;3(1). https://doi.org/10.1016/j.jacig.2023.100195.

Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531–9. https://doi.org/10.1093/bjd/ljad240.

Article  PubMed  Google Scholar 

Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023;401(10372):204–14. https://doi.org/10.1016/S0140-6736(22)02037-2.